# A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

> **NCT06073873** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 3000 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT06073873
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06073873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06073873, "A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06073873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*